Renalytix AI PLC Result of AGM (2137O)

TIDMRENX

RNS Number : 2137O

Renalytix AI PLC

30 September 2019

Renalytix AI plc

("RenalytixAI" or the "Company")

Result of AGM

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announces at its annual general meeting held earlier today, the following resolutions were passed on a show of hands with the table below summarising proxy votes:

 
       Resolution                                 Votes for*   Votes against   Votes withheld 
       To receive the audited accounts 
 1.     of the Company                            24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
 2.    To re-elect Julian Baines                  24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
 3.    To re-elect Christopher Mills              20,570,985       3,910,826                0 
      -----------------------------------------  -----------  --------------  --------------- 
 4.    To re-elect Richard Evans                  24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
 5.    To re-elect Fergus Fleming                 24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
 6.    To elect Doctor Erik Lium                  24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
 7.    To elect James McCullough                  24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
 8.    To elect Barbara Murphy                    24,481,811               0                0 
      -----------------------------------------  -----------  --------------  --------------- 
       To re-appoint the auditors PKF 
        Littlejohn LLP and authorise 
 9.     the Directors to fix their remuneration   24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
       To authorise the directors to 
        replace the existing authority 
        to allot shares in the Company 
        in connection with s551 of the 
 10.    Companies Act 2006                        24,481,789              22                0 
      -----------------------------------------  -----------  --------------  --------------- 
       To authorise the directors to 
        allot Relevant Securities as 
        if s561 of the Companies Act 
 11.    2006 did not apply                        23,769,147         702,664           10,000 
      -----------------------------------------  -----------  --------------  --------------- 
 

*Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.

For further information, please contact:

 
Renalytix AI plc                                                                 www.renalytixai.com 
James McCullough, CEO                                                                Via Walbrook PR 
 
Stifel (Nominated Adviser & Joint Broker)                                         Tel: [phone] 
Alex Price / Jonathan Senior / Ben Maddison 
 
N+1 Singer (Joint Broker)                                                         Tel: [phone] 
Aubrey Powell / James White / George Tzimas (Corporate Finance) 
 Tom Salvesen / Mia Gardner (Corporate Broking) 
 
 
 
Walbrook PR Limited                                   Tel: [phone] or [e-mail] 
Paul McManus / Lianne Cawthorne                                       Mob: [phone] 
                                                                                                 303 
 
 

About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGEASNEDDANEFF

(END) Dow Jones Newswires

September 30, 2019 11:37 ET (15:37 GMT)